Literature DB >> 10389941

Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus.

J D Bradley1, Y Kataoka, S Advani, S M Chung, R B Arani, G Y Gillespie, R J Whitley, J M Markert, B Roizman, R R Weichselbaum.   

Abstract

Malignant gliomas remain incurable with current interventions. Encouraging investigational approaches include the use of genetically modified herpes simplex-1 (HSV-1) viruses as direct cytotoxic agents. Combining attenuated HSV-1 with standard therapy, human U-87 malignant glioma xenografts grown in the hind limb or intracranially in athymic nude mice were exposed to ionizing radiation, inoculated with genetically modified HSV R3616, or received both virus and radiation. The combination of virus with fractionated ionizing radiation suggests a synergistic action and results in reduced tumor volumes and longer survivals when compared with treatment with either modality alone.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10389941

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

Review 1.  Oncolytic Virotherapy for the Treatment of Malignant Glioma.

Authors:  Paul M Foreman; Gregory K Friedman; Kevin A Cassady; James M Markert
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 2.  Oncolytic viral therapy of malignant glioma.

Authors:  Jacqueline Nuss Parker; David F Bauer; James J Cody; James M Markert
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

3.  Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.

Authors:  Alicia M Waters; James M Johnston; Alyssa T Reddy; John Fiveash; Avi Madan-Swain; Kara Kachurak; Asim K Bag; G Yancey Gillespie; James M Markert; Gregory K Friedman
Journal:  Hum Gene Ther Clin Dev       Date:  2017-03       Impact factor: 5.032

4.  The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment.

Authors:  W Hans Meisen; Eric S Wohleb; Alena Cristina Jaime-Ramirez; Chelsea Bolyard; Ji Young Yoo; Luke Russell; Jayson Hardcastle; Samuel Dubin; Kamaldeen Muili; Jianhua Yu; Michael Caligiuri; Jonathan Godbout; Balveen Kaur
Journal:  Clin Cancer Res       Date:  2015-03-31       Impact factor: 12.531

5.  Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer.

Authors:  T J Jorgensen; S Katz; E K Wittmack; S Varghese; T Todo; S D Rabkin; R L Martuza
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

Review 6.  Oncolytic virus therapy using genetically engineered herpes simplex viruses.

Authors:  Tomoki Todo
Journal:  Hum Cell       Date:  2002-09       Impact factor: 4.174

7.  Glucose metabolism heterogeneity in human and mouse malignant glioma cell lines.

Authors:  Corinne E Griguer; Claudia R Oliva; G Yancey Gillespie
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

8.  Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM.

Authors:  James M Markert; Peter G Liechty; Wenquan Wang; Shanna Gaston; Eunice Braz; Matthias Karrasch; Louis B Nabors; Michael Markiewicz; Alfred D Lakeman; Cheryl A Palmer; Jacqueline N Parker; Richard J Whitley; George Y Gillespie
Journal:  Mol Ther       Date:  2008-10-28       Impact factor: 11.454

9.  A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.

Authors:  James M Markert; Shantanu N Razdan; Hui-Chien Kuo; Alan Cantor; Anette Knoll; Matthias Karrasch; L Burt Nabors; Michael Markiewicz; Bonita S Agee; Jennifer M Coleman; Alfred D Lakeman; Cheryl A Palmer; Jacqueline N Parker; Richard J Whitley; Ralph R Weichselbaum; John B Fiveash; G Yancey Gillespie
Journal:  Mol Ther       Date:  2014-02-27       Impact factor: 11.454

Review 10.  Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.

Authors:  Ryuichi Kanai; Samuel D Rabkin
Journal:  CNS Oncol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.